| Outcome Measures: |
Primary: Maximum plasma concentration of Empagliflozin, Cmax of Empagliflozin, Time Frame: 0 hour ~ 48 hour after drug administration|Maximum plasma concentration of Metformin, Cmax of Metformin, Time Frame: 0 hour ~ 48 hour after drug administration|Area under the plasma concentration of Empagliflozin-time curve from time zero to time of last measurable concentration, AUClast of Empagliflozin, Time Frame: 0 hour ~ 48 hour after drug administration|Area under the plasma concentration of Metformin-time curve from time zero to time of last measurable concentration, AUClast of Metformin, Time Frame: 0 hour ~ 48 hour after drug administration | Secondary: Area under the plasma concentration of Empagliflozin-time curve from time zero to infinity, AUCinf of Empagliflozin, 0 hour ~ 48 hour after drug administration|Area under the plasma concentration of Metformin-time curve from time zero to infinity, AUCinf of Metformin, 0 hour ~ 48 hour after drug administration|Time to reach maximum (peak) plasma concentration of Empagliflozin following drug administration, Tmax of Empagliflozin, 0 hour ~ 48 hour after drug administration|Time to reach maximum (peak) plasma concentration of Metformin following drug administration, Tmax of Metformin, 0 hour ~ 48 hour after drug administration|Half-life of Empagliflozin, t1/2 of Empagliflozin, 0 hour ~ 48 hour after drug administration|Half-life of Metformin, t1/2 of Metformin, 0 hour ~ 48 hour after drug administration|Apparent clearance of Empagliflozin, CL/F of Empagliflozin, 0 hour ~ 48 hour after drug administration|Apparent clearance of Metformin, CL/F of Metformin, 0 hour ~ 48 hour after drug administration|Apparent volume of distribution of Empagliflozin, Vd/F of Empagliflozin, 0 hour ~ 48 hour after drug administration|Apparent volume of distribution of Metformin, Vd/F of Metformin, 0 hour ~ 48 hour after drug administration
|
